Leflunomide Orion

Leflunomide, the active ingredient in Leflunomide Orion, is a dihydroorotate dehydrogenase inhibitor presented as a tablet for oral use. It is indicated for the treatment of rheumatoid arthritis and psoriatic arthritis in adult patients, helping to reduce joint inflammation and slow disease progression.

GNH USA supplies Leflunomide Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across EU and global markets. The company provides full batch traceability and adheres to Good Distribution Practice standards for every shipment.

Leflunomide is a disease-modifying antirheumatic drug (DMARD) that modulates inflammatory pathways in autoimmune arthritis.

- Rheumatoid arthritis: reduces joint swelling, pain and slows structural damage. - Psoriatic arthritis: improves skin lesions and joint symptoms, decreasing disease activity. - Inadequate response to methotrexate: offers an alternative therapeutic option to achieve disease control.

Leflunomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Alopecia: thinning or loss of hair. - Elevated liver enzymes: mild increase in ALT/AST.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Bone marrow suppression: anemia, leukopenia, thrombocytopenia. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Leflunomide therapy, several safety considerations should be reviewed.

- Liver function monitoring: assess baseline enzymes and repeat regularly. - Hematologic monitoring: check complete blood count for cytopenias. - Pregnancy avoidance: drug is contraindicated in pregnancy; effective contraception required. - Hypertension surveillance: monitor blood pressure during treatment. - Drug interactions: review concomitant medications for potential major interactions. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and light.

Leflunomide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Teriflunomide: combined use may increase risk of hepatotoxicity. - Azathioprine or cyclophosphamide: additive bone marrow suppression. - Strong CYP1A2 inducers (e.g., rifampicin): may reduce leflunomide plasma levels.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Methotrexate: concurrent use can increase hepatic toxicity risk.